Daily oral MK-677 significantly increased growth hormone and IGF-1 levels in healthy elderly adults to ranges seen in younger people, without serious side effects.
Youthful GH levels restoredOral MK-677 raised GH and IGF-1 levels in elderly adults (64-81 years) toward ranges typical of younger individuals
What the researchers found
Daily oral MK-677 significantly stimulated the GH-IGF-1 axis in healthy elderly adults aged 64-81, raising levels toward those seen in younger individuals.
Why it matters
Declining growth hormone is associated with aging-related muscle loss, fat gain, and cardiovascular risk. An oral compound that safely restores youthful GH levels could have significant anti-aging applications.
How the study worked
Randomized controlled trial with 32 healthy elderly subjects (15 women, 17 men, aged 64-81). Participants received oral MK-677 daily, and GH and IGF-1 levels were measured.
What this study cannot tell us
Relatively small sample size. Short-term study; long-term effects and safety not established. Functional outcomes (muscle mass, strength, body composition) were not the primary endpoints.
How to read the evidence
Strong evidence from a randomized controlled trial in human elderly subjects. Well-designed but relatively small and short-term.
When this study was published
Published in 1996, this was one of the earliest RCTs of oral MK-677 in elderly populations. Subsequent studies have confirmed and extended these findings.
The bigger picture
This study was pivotal in establishing MK-677 as a viable oral GH secretagogue for elderly populations, offering a more practical alternative to GH injections for combating age-related hormonal decline.
Questions still open
- Does MK-677's GH stimulation translate to meaningful improvements in muscle mass and function in elderly adults?
- What are the long-term safety implications of chronically elevated GH/IGF-1 levels in aging populations?
Common questions
What is MK-677?
Why does growth hormone decline matter in aging?
Read the original research
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
The Journal of clinical endocrinology and metabolism, 81(12), 4249-57
Citation
Chapman, I M; Bach, M A; Van Cauter, E; Farmer, M; Krupa, D; Taylor, A M; Schilling, L M; Cole, K Y; Skiles, E H; Pezzoli, S S; Hartman, M L; Veldhuis, J D; Gormley, G J; Thorner, M O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.. The Journal of clinical endocrinology and metabolism, 81(12), 4249-57.